The share price of Valeant Pharmaceuticals International Inc. dropped nearly 40 per cent Wednesday and trading was halted twice after controversial short-seller Citron Research published a report questioning whether the Laval, Que.-based company could be the “Pharmaceutical Enron.”
The report lowered its target for Valeant to US$50 from over US$200, saying that it had a “smoking gun” uncovering undisclosed relationships with specialty pharmaceutical companies. Details